methapyrilene Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central MeSH PubChem

Active Ingredient History

NOW
  • Now
Methapyrilene is an antihistamine and anticholinergic of the pyridine chemical class which was developed in the early 1950s. It was sold under the trade names Co-Pyronil and Histadyl EC. It has relatively strong sedative effects, to the extent that its primary use was as a medication for insomnia rather than for its antihistamine action. Together with scopolamine, it was the main ingredient in Sominex, Nytol, and Sleep-Eze. It also provided the sedative component of Excedrin PM. Manufacturers voluntarily withdrew methapyrilineb drug products from the market in May and June 1979, when methapyrilene was demonstrated to cause liver cancer in rats when given chronically.   NCATS

Chemistry

More Chemistry

Pharmacology

Alternative names

1612 | 2-[[2-(dimethylamino)ethyl]-2-thenylamino]pyridine | metapyrilene | methapyrilene | methapyrilene hcl | methapyrilene hydrochloride | methypyrilene | n,n-dimethyl-n'-pyrid-2-yl-n'-2-thenylethylenediamine | paradormalene | pyrinistab | pyrinistol | thenylene | thenylene hcl | thenylpyramine | thenylpyramine hcl

Organizations (1)

Research & Development (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (3)

Approved Indications (1)


 

Hypersensitivity

Experimental Indications - Clinical Trial Phases 1-4 (2)


 

Cognitive Dysfunction (Phase 4)

Hypersensitivity, Immediate ()

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1
  • # of Trial Organizations: 1

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue